Pharmatech Announces Key Hires and New Structure to Support Growth Initiative

January 27, 2015

,

 

Bikash Chatterjee Named President and Chief Scientific Officer

HAYWARD, Calif.—January 27, 2015—Pharmatech Associates has appointed Bikash Chatterjee to the position of President and Chief Scientific Officer (CSO). Mr. Chatterjee served as the company’s Chief Technology Officer where he established the Pharmatech Ecosystem™ as the company’s design for its four distinct consulting service offerings.

As Chief Scientific Officer, Chatterjee will be responsible for growing the company’s consulting services through its four spheres of technical expertise: Validation, Product and Process Development, Regulatory, and Compliance.

Pharmatech announced the following additions to their Senior Leadership Team:
– Wai Wong, Vice President, Validation. Mr. Wong brings 20 years of equipment, facility and process validation experience in the pharmaceutical, medical device, and biologic industries. Wong has earned an international reputation for expertise in Validation having demonstrated success in navigating the complex requirements of the FDA, EU and PIC/s compliance. Pharmatech was founded as a qualification and validation firm and Wong will continue to shepherd this practice area.
– Jorge Basso, Vice President of Product and Process Development. Mr. Basso brings 23 years of process and product design experience in the pharmaceutical, medical device, biologic and cosmetic industries, with expert knowledge of the key components of a successful product development program including compliance, regulatory strategy and validation.
– Richard Aleman, Vice President of Regulatory Compliance, a 28-year veteran of the U.S. Food and Drug Administration, brings supervisory experience in the regulatory and enforcement arenas, with knowledge of the compliance issues confronting the drug, biologics, medical devices and dietary supplement industries. His international experience includes assignments with the Food and Agricultural Organization of the United Nations (FAO), US AID, the World Health Organization (WHO), and the United States Pharmacopeia (USP), where he was lead auditor.

“As we enter our third decade, Pharmatech’s growth strategy centers on our Pharmatech Ecosystem and deploying our Quality by Design and Quality Risk Management tools on behalf of our clients,” said Warren Baker, Chief Executive Officer, Pharmatech Associates. “Today, with engagements in the biotech arena, our work depends on understanding our client’s scientific foundations. Bikash’s contributions as Chief Scientific Officer will set new higher standards for our work as best-in-class service providers with a mission of compliance through science.”

“Pharmatech’s ecosystem is based on expert knowledge in all four practice areas at the leadership team level. Our team is exceptional in their knowledge of their specific practice areas and in the breadth and depth of experience in the life sciences,” said Bikash Chatterjee. “To remain competitive requires a complex mix of technical knowledge, practical business experience and broad regulatory compliance understanding, wrapped up in a culture of precise execution. That has been our recipe for success since 1995 and, as we enter our 20th year of business, it is the foundation for our future success.”

About Pharmatech Associates
Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech’s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Product and Process Development, Compliance, Regulatory, and Validation. This interconnected framework of services denotes the Pharmatech EcosystemTM. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area.
==
Press contact:
Judy Curtis—SIPR for Pharmatech
+ 1 650-274-1509
judy@sipr.com